Summary by Moomoo AI
On May 14, 2024, Novavax's President of R&D, Filip Dubovsky, completed a significant transaction involving the company's common stock. Dubovsky executed a sale of 47,312 shares at a price of $13.90 per share, resulting in a total market value of $657,636.80. Prior to this sale, Dubovsky acquired 19,652 shares through the exercise of derivative securities at a price of $6.97 each. Following these transactions, Dubovsky's direct holdings in Novavax amounted to 38,953 shares of common stock.